Research peptides
TB 500 (Timosina Beta 4)
Available documentary data and items still to verify are detailed below.
Price incl. VAT€90.00
AvailabilityAvailable
SKUTB 500
Loading availability…
02 — Information to verify
Product details
Overview
TB-500 is a name associated with a fragment of thymosin β4. The peptide fragment must be distinguished from the full protein: its name, sequence, and terminal modifications define different molecular species.
Structure and technical data
Technical data
Catalog format: 10 mg. The listed structural record describes Ac-LKKTETQ, a seven-residue fragment with N-terminal acetylation. Its formula and mass include the acetyl group.
- Sequence
- Ac-LKKTETQ
- Molecular formula
- C38H68N10O14
- Reported molecular mass
- 889.0 g/mol
- CAS number
- 885340-08-9
- PubChem CID
- 62707662
- Reported synonyms
- QHK6Z47GTG
Reference molecular data.
View the PubChem record — PubChem CID 62707662
The record describes the N-acetylated fragment Ac-LKKTETQ, not full-length thymosin β4. Formula and mass include the acetylation, which is absent from the abbreviated sequence LKKTETQ.
Research context
Research considers cell migration, actin, and extracellular-matrix remodelling. The cited analytical paper examines identification of TB-500 and its metabolites by chromatography and mass spectrometry. Studies of full-length thymosin β4 do not automatically establish the same properties for the fragment.
Fragment, acetylation, and thymosin β4Actin, migration, and cellular organisationExtracellular matrix, collagen, and MMP/TIMPBiomaterials, immunomodulation, and muscleLC-MS identification and metabolites
Fragment, acetylation, and thymosin β4
The seven-residue fragment and full-length thymosin β4 are different experimental entities. N-terminal acetylation changes formula and mass without changing the seven sequence letters. Comparing studies requires material identity, termini, and analytical methods rather than the TB-500 name alone.
Actin, migration, and cellular organisation
Actin dynamics connect the cytoskeleton with adhesion and cell movement. In thymosin-β4-family research, migration, proliferation, and differentiation describe different processes. Fragment research must determine which full-protein interactions are retained rather than assuming they all transfer.
Extracellular matrix, collagen, and MMP/TIMP
Tissue remodelling depends on both matrix deposition and degradation. Metalloproteinases (MMPs) and their inhibitors (TIMPs) are studied within this balance. The liver-fibrosis review describes these general mechanisms; it is not an experiment establishing the same effects for the TB-500 fragment.
Biomaterials, immunomodulation, and muscle
Biomaterials research includes supporting matrices, controlled signal release, macrophage polarisation, and stem-cell interactions. Some papers evaluate muscle repair and transcriptomes after volumetric muscle loss. These are studies of complex platforms, not evidence that peptide alone reproduces every result.
10.1002/jbm.a.37239 10.1016/j.bioactmat.2021.04.017 10.1186/s12891-023-06401-1
LC-MS identification and metabolites
The 2012 analytical paper studies TB-500 in equine urine and plasma using liquid chromatography and mass spectrometry. Separation, fragmentation, and metabolite recognition distinguish it from related peptides. A detection method does not establish biological efficacy or safety.
References
- Thymosin β4: a multi-functional regenerative peptide
- Thymosin beta-4 improves endothelial function
- Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography–mass spectrometry
- Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis
- Promoting endogenous repair of skeletal muscle using regenerative biomaterials
- Promoting musculoskeletal system soft tissue regeneration by biomaterial-mediated modulation of macrophage polarization
- Transcriptome profiling of a synergistic volumetric muscle loss repair strategy
Catalog of products presented for research activities. Not for human or veterinary use. This notice does not replace verification of applicable rules.